Please enable Javascript
Josep M. Llovet, MD
Josep M. Llovet, MD, Mount Sinai
Articles by Josep M. Llovet, MD
LEAP-012: PFS Benefit With Pembrolizumab, Levatinib, and TACE vs TACE Alone
Josep M. Llovet, MD
GI Cancer
|
March 13, 2025
Dr. Josep Llovet discusses promising data, including higher PFS and OS, in metastatic liver cancer from the LEAP-012 trial.
View More
LEAP-002: IO/VEGF Versus IO/IO Versus IO/TKI
Josep M. Llovet, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Llovet and Finn consider how LEAP-002 adds to the debate around IO/VEGF, IO/IO, and IO/TKI for aHCC.
View More
LEAP-002: Lenvatinib Plus Pembrolizumab for First-Line Advanced HCC?
Josep M. Llovet, MD
Hepatocellular Carcinoma
|
March 13, 2025
Drs. Llovet and Finn provide a high-level understanding of LEAP-002, looking at lenvatinib/pembrolizumab for 1L aHCC.
View More